At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
In Brief
A Phase 2 clinical trial evaluating Biospecimen Collection, Bone Scan, and 5 other interventions for Locally Advanced Papillary Renal Cell Carcinoma and 6 related conditions. Completed, enrolled 152 participants across 595 sites in 2 countries.
Detailed Summary
This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving cabozantinib s-malate, crizotinib, or savolitinib will work better in treating patients with kidney cancer compared to sunitinib malate.
Study Details
Timeline
Interventions
Undergo collection of plasma and serum samples
Undergo bone scan
Given PO
Undergo CT
Given PO
Given PO
Given PO